Management & Key Personnel

Marty Haslanger Haslanger joined Ribonomics as Vice Chairman in January of 2006. Prior to that he co-founded Amphora Discovery Corporation in September 2001. As President and CEO, he built the company to be a unique discovery engine with multiple projects at the IND-enabling stage. He moved to the Vice Chairman role in January of 2005. He has 28 years of pharmaceutical and biotechnology industry experience. Previously he served as Executive Director of Research Technologies and President of Sphinx Labs, at Eli Lilly and Company. Previously, he was Director of Cardiovascular and CNS Medicinal Chemistry at the Schering-Plough Research Institute. He began his pharmaceutical career at the Squibb Institute for Medical Research in Princeton, N.J., now part of BMS. Dr. Haslanger received his Ph.D. in Organic Chemistry from the University of Michigan and completed a postdoctoral fellowship at Harvard University. His scientific and technical work is described in numerous patents, publications, and presentations.

Dr. Cheatham joined Ribonomics, Inc. in January 2002. Prior to this, Dr. Cheatham was Director of Cell Therapy at Artecel Sciences, Inc, in RTP, NC. Prior to that, Dr. Cheatham held a joint appointment as a Principal Investigator at the Joslin Diabetes Center and as an Assistant Professor at Harvard Medical School. While at Harvard, Dr. Cheatham published extensively in the areas of molecular mechanisms of insulin action, adipocyte cell biology and obesity. Drawing on his extensive experience in these areas, Dr. Cheatham is presently applying Ribonomics’ technology platform to the analysis of pancreatic ß-cell function, obesity and insulin action in adipocytes. He graduated from King College with a B.S. in Biology and earned his M.S. and Ph.D. degrees in Biochemistry at the University of Tennessee at Knoxville.

Dr. Henderson joined the Company in April 2001 as the Company’s first scientist. Prior to joining Ribonomics, Dr. Henderson was an Assistant Research Professor in Microbiology at Duke University Medical Center, where his research interests were focused on studying protein-RNA interactions. He was recruited to Duke by company founder, Dr. Jack Keene. Prior to that, Dr. Henderson worked at Chemgenics Pharmaceuticals, a functional genomics biotechnology company located in Boston, MA. Prior to joining Chemgenics, Dr. Henderson consulted for Cubist Pharmaceuticals, developing the Company’s initial informatics systems. Dr. Henderson received his post-doctoral training at M.I.T. in the area of protein-nucleic acid recognition. He graduated from the University of Tennessee at Chattanooga with a B.S. in Chemistry and Purdue University with a Ph.D. in Biochemistry.